Does the Development of Cancer Drugs Yield Exorbitant Profits?

A Review of the JAMA Network Open Article by Tay-Tao et al.

Partner Richard Manning reviews the article "Comparison of Sales Income and Research Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies," published in JAMA Network Open. Dr. Manning comments on the absence of a scientific approach to the article's main question and on the argument that drug companies make excessive profits by developing cancer drugs.